Cara Therapeutics (CARA)
(Delayed Data from NSDQ)
$0.35 USD
-0.01 (-3.61%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $0.34 -0.01 (-3.63%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CARA 0.35 -0.01(-3.61%)
Will CARA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CARA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CARA
Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
Cara Therapeutics (CARA) Reports Q4 Loss, Tops Revenue Estimates
CARA: What are Zacks experts saying now?
Zacks Private Portfolio Services
CARA's Late-Stage Skin Disease Study Fails, Stock Plummets 49%
Cara (CARA) Reports Q3 Earnings: What Key Metrics Have to Say
Pliant Therapeutics, Inc. (PLRX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Other News for CARA
Cara Therapeutics Announces Exploration of Strategic Alternatives
Bearish Friday For Marijuana Stocks - Global Compliance, 1933 Industries Among Top Gainers
Cannabis Stock Gainers And Losers From June 27, 2024
Bullish Wednesday For Marijuana Stocks - Affinor Growers, Blueberries Medical Among Top Gainers
Bearish Sentiment Across The Cannabis Space - Check Full Movers For June 25, 2024